BigHat Biosciences raises $75M to design safer, more effective antibodies
A company developing safer, more effective antibody therapies for patients using machine learning and synthetic…
A company developing safer, more effective antibody therapies for patients using machine learning and synthetic…
FORTY51 Ventures has announced the closing of FORTY51 Ventures I, raising $43 million in its…
The first-round of financing to the tune of $21 million (€20.6 million), for a drug…
A bio-based vitamin B7 is the first product to be commercialized as biotech company, Biosyntia,…
French pharmaceutical company, Juvisé has just bought worldwide commercial rights to Pylera from US biopharmaceutical…
A Paris-based biotech company developing products for auto-immune diseases, announced today (June 30) that it…
A grant of €10 million ($10.5 million) has been secured by pharmaceutical company Osivax to…
A bio-manufacturing company based in Shanghai has bagged $80 million in funding to advance its…
Pfizer has agreed to invest €90.5 million ($95 million) towards a vaccination for Lyme disease. …
U.S. company Third Rock Ventures has closed Third Rock Ventures Fund VI, raising $1.1 billion. …
European life sciences venture capital firm Forbion, has announced the first €470M ($500M) close of…